The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Promising targets in multiple myeloma: BCMA, GPRC5D, and FcRH5
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, comments on the emerging landscape of novel targets in multiple myeloma, including BCMA, GPRC5D, and FcRH5, with ongoing clinical trials exploring combination therapies and sequencing strategies. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in multiple myeloma, currently we have CAR-T, two CAR-T products that are FDA approved that target BCMA. And with bispecific antibodies, we also have one that’s targeting something outside BCMA, GPRC5D. So it’s very exciting to see that we have clinical trial results with bispecifics, with also GPRC5D and FcRH5, or FcRL5 is another name for it. And so we’re hoping that this third novel target could be potentially coming into standard of care practice as well for our patients...
So in multiple myeloma, currently we have CAR-T, two CAR-T products that are FDA approved that target BCMA. And with bispecific antibodies, we also have one that’s targeting something outside BCMA, GPRC5D. So it’s very exciting to see that we have clinical trial results with bispecifics, with also GPRC5D and FcRH5, or FcRL5 is another name for it. And so we’re hoping that this third novel target could be potentially coming into standard of care practice as well for our patients. And in clinical trials, we’re looking at how BCMA and GPRC5D might be combined, either in sequence or even with new drugs that could be targeting both. So I think these are all very novel targets that are coming into the clinical space. It’s also interesting to see that some of the side effect profiles with these antigens are different. And so really trying to understand which patients are at risk for developing some of these or how to identify these risks early in managing or mitigating some of these side effects would be very, very important to really help make these usable for standard of care practice.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
